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Ali Shawki and Declan F. McCole
Division of Biomedical Sciences, University of California Riverside, Riverside, CaliforniaSUMMARY
Expansion of pathobionts such as adherent-invasive
Escherichia coli during inflammation is associated with in-
flammatory bowel disease and contributes to intestinal
epithelial barrier dysfunction. This review discusses mech-
anisms by which these bacteria disrupt epithelial barrier
and tight junction function.
Pathobiont expansion, such as that of adherent-invasive
Escherichia coli (AIEC), is an emerging factor associated
with inflammatory bowel disease. The intestinal epithelial
barrier is the first line of defense against these pathogens.
Inflammation plays a critical role in altering the epithelial
barrier and is a major factor involved in promoting the
expansion and pathogenesis of AIEC. AIEC in turn can
exacerbate intestinal epithelial barrier dysfunction by
targeting multiple elements of the barrier. One critical
element of the epithelial barrier is the tight junction.
Increasing evidence suggests that AIEC may selectively
target protein components of tight junctions, leading to
increased barrier permeability. This may represent one
mechanism by which AIEC could contribute to the devel-
opment of inflammatory bowel disease. This review article
discusses potential mechanisms by which AIEC can disrupt
epithelial tight junction function and intestinal barrier
function. (Cell Mol Gastroenterol Hepatol 2017;3:41–50;
http://dx.doi.org/10.1016/j.jcmgh.2016.10.004)
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microbiome, and can result in the promotion of pathobiont
expansion.1 A clinically important example of this involves
the expansion of the adherent-invasive Escherichia coli
(AIEC) LF82, originally isolated from ileal mucosa of a
Crohn’s disease patient.2 Crohn’s disease (CD) and ulcera-
tive colitis (UC) are multifaceted conditions that collectively
are referred to as inflammatory bowel disease (IBD).3,4
Factors contributing to IBD onset and development
include dysregulation of gut bacteria and an increase in
intestinal epithelial barrier permeability.1 This review
article discusses the emergence of AIEC as a potential
pathogenic factor in IBD and the molecular mechanisms
through which it disrupts intestinal epithelial homeostasis
and tight junction (TJ) integrity.AIEC
Although the etiology of IBD is unknown, many in-
vestigators have probed whether a pathogenic cause can be
attributed to onset of disease, either in full or in part.5–7
Although no pathogen has been shown consistently to be
associated with IBD, a subset of CD patients do show
increased prevalence of a unique enteropathogenic strain of
the B2 phylotype E coli termed AIEC.2,8,9 Ileal biopsy spec-
imens from CD and UC patients have shown that AIEC are
associated primarily with CD; however, more recent studies
have shown an equal prevalence of AIEC strains in UC as
well as CD, suggesting that this pathobiont may have a
greater association with IBD than first thought.10–12
Although LF82 is the most referenced AIEC, it is only one
of many AIEC strains that were found in IBD patients.2,13
It has been remarkably difficult to identify a specific
genetic or molecular marker of AIEC, thus in vitro assays are
used to validate AIEC.14 However, there may be some ge-
netic signatures that differ between the B2 AIEC phylotype
compared with other AIEC phylotypes.12 One potential AIEC
candidate gene is the novel AIEC serine protease Vat-AIEC,
which promotes expansion and adherence of AIEC to
intestinal epithelial cells (IECs).15 Expression of this gene
was approximately 3-fold higher in CD-AIEC isolates
compared with non-AIEC isolates from CD patients or
healthy subjects.15 It therefore could be considered a se-
lective rather than an exclusive genetic marker for AIEC.
AIEC are distinct from other strains of E coli because
they show nonclassic virulence factors of adherence and
invasion (ie, lack of a type III secretion system).13 Notably,
AIEC pathogenesis involves survival and replication in IECs
and macrophages in vivo and in vitro that further
42 Shawki and McCole Cellular and Molecular Gastroenterology and Hepatology Vol. 3, No. 1exacerbated barrier dysfunction, this topic is discussed
later (Figure 1).9,13 Martinez-Medina and Garcia-Gil16
published an excellent comprehensive review on the defi-
nition, characteristics, and molecular basis of AIEC
pathogenicity.Interaction of AIEC With IECs
The intestine is lined by a single layer of epithelial cells that
are interconnected by transmembrane proteins to create
physical connections with one another and to form a selec-
tively permeable barrier.17 This leaky barrier serves multipleFigure 1. Effect of AIEC
on major junctional pro-
teins and regulatory
pathways in simplified
IECs. Indirect internaliza-
tion of TJ proteins by a
micropinocytosis process
can occur as a result of
AIEC direct or indirect
TNF-a–dependent activa-
tion of NF-kB, leading to
increased expression of
MLCK and cytoskeletal
contraction. AIEC interac-
tion with IECs results in
direct internalization of TJ
proteins and indirectly by
activation of proin-
flammatory cytokines. In-
testinal barrier permeability
is compromised, permit-
ting the internalization,
survival, and replication of
AIEC, invasion of macro-
phages, and further exac-
erbation of barrier
permeability. pMLC,
phosphorylated MLC; Th,
T-helper cell.
January 2017 AIEC Disruption of Epithelial Junctions 43functions that are essential for intestinal homeostasis: gener-
ation of ion solute concentration gradients, absorption of nu-
trients, antimicrobial peptide secretion (reviewed by McCole
and Barrett18), and protection of the host from toxins and
pathogens (reviewed by Peterson and Artis19). Disruption of
barrier function can lead to loss of microbiome diversity and
promotion of AIEC expansion and pathogenesis.1,6
IECs express molecular sensors that sample the luminal
content for bacterial antigens, and in some cases the bacteria
itself, and translate this information to host immune cells.19
This process prevents the host immune system from a
robust proinflammatory response against commensal bac-
teria while maintaining the ability to protect against patho-
gens. The first identified IBD-associated gene, cytoplasmic
nucleotide-binding oligomerization domain 2 (NOD2/
CARD15), a NOD-like receptor family member, serves as a
sensor to bacterial peptidoglycans (BPs) (reviewed by Phil-
pott et al20). Binding of BPs to NOD2 results in the activation
of nuclear factor–kB (NF-kB) and autophagolysis,21 and the
appearance of NOD2 at the site of bacterial endocytosis in
epithelial cells drives autophagolysis.20 Mutations in NOD2
result in an increased immune response to bacteria and
bacterial antigens22 that is accompanied by impaired auto-
phagolysis of AIEC and subsequently survival of AIEC in im-
mune cells.23,24 Conversely, overexpression of NOD2 and
other genes involved in autophagy (eg, by activation of the
eukaryotic translation initiation factor 2 alpha kinase 4-
eukaryotic translation initiation factor 2 alpha-activating
transcription factor 4 [EIF2AK4-EIF2A-ATF4] pathway), re-
sults in an increased autophagy response to AIEC and a
reduction in AIEC survival in macrophages.25–27 Thus,
functional autophagolysis in both intestinal epithelial cells
and macrophages is required for AIEC degradation and
prevention of AIEC-induced barrier dysfunction.24
It is clear that proinflammatory cytokine signaling plays a
major role in altered intestinal permeability28 and this may be
associatedwith AIEC pathogenesis. Loss of negative regulation
of proinflammatory cytokines (eg, interferon-g [IFN-g] and
tumor necrosis factor-a [TNF-a]), and, conversely, over-
stimulation of the proinflammatory response, plays a role in
altered intestinal permeability and thismay be associatedwith
AIEC expansion and pathogenesis.22,29–31 A key mediator of
signaling by many cytokines, NF-kB has been shown to regu-
late the development and response of the immune system,
inflammation, and cancer.32 Defective NF-kB activation can
result in a defective immune cell response to BPs (driven by
interleukin [IL]8) and bacterial lipopolysaccharides, and
defective autophagy.33–35 Taken together, dysfunctional
regulation of proinflammatory cytokines may be associated
with an inappropriate response to AIEC andmay play a role in
the promotion of AIEC expansion and pathogenesis.AIEC Adherence
With respect to the clinical intersection between altered
expression of genes in IBD and genes involved in AIEC
expansion, patients who are at risk of developing
CD also overexpress carcinoembryonic antigen–related
cell-adhesion molecule 6 (CEACAM6), placing them at ahigher risk for AIEC adherence and invasion via interaction
of bacterial type 1 pili and long polar fimbriae (LPF) to host
CEACAM6.36 CEACAM6, normally expressed on the apical
membrane of human epithelial cells from the large intes-
tine,37 is regulated by the proinflammatory cytokines IFN-g
and TNF-a.36,38 Studies using isolated human Peyer’s
patches or mouse ileal biopsy specimens containing Peyer’s
patches showed that bacterial pili specifically targeted
Peyer’s patch M-cells (discussed later) expressing CEA-
CAM6; however, LPF-independent AIEC invasion and
adherence also has been shown in other types of intestinal
epithelial cells.36,39 Nevertheless, AIEC can up-regulate
CEACAM6 indirectly via activation of proinflammatory
cytokines,40 thus leading to increased expression of
CEACAM6 and further binding and internalization of AIEC.
Carcinoembryonic antigen human bacterial artifical
chromosome 10 (CEABAC10) transgenic mice that over-
express human CEACAMs show no clinical evidence of co-
litis; however, these same mice infected with AIEC show a
barrier defect.41 It would be expected, therefore, that pa-
tients with NOD2 mutations and/or increased expression of
ileal CEACAM6 are more at risk to develop IBD. In support
of this statement, CEACAM6 and the pore-forming TJ protein
claudin-2, isolated from ileal biopsy specimens of CD pa-
tients, are not only co-localized, but expression levels are
both increased compared with control subjects,41 thereby
promoting a favorable environment for AIEC adherence and
invasion and further exacerbation of barrier dysfunction,
ultimately leading to a vicious cycle of proinflammatory
cytokine release and increased barrier permeability. Inter-
estingly, although CEACAM6 is overexpressed in ileal mu-
cosa of IBD patients, the protein is not normally expressed
in ileal mucosa.41 The mechanism(s) regulating CEACAM6
expression in IBD currently are not known.AIEC Invasion
The mechanism of AIEC internalization involves macro-
pinocytosis and vacuolization of the bacteria into IECs and
macrophages.9,42–44 AIEC have been found in late endosomes
of intestinal epithelial cells, as evident by co-localization with
the lysosomal marker lysosomal-associated membrane pro-
tein-1 (LAMP1).24,44 Similarly, Mycobacterium avium subspe-
cies paratuberculosis has been localized in endosomes of
intestinal epithelial cells.45 The process of internalization into
endosomes also occurs during reorganization of TJs and is
discussed later. AIEC-containing endosomes mature into
phagolysosomes, which then can exit IECs, as discussed later.
Alternatively, AIEC replication is permitted in autophagolysis-
deficient, AIEC-containing phagosome/endosome/lysosomes,
leading to loss of organelle membrane integrity, release of the
bacteria into the cytoplasm, and basolateral exit of the bacteria
from the IEC (Figure 1).46,47 AIEC translocation through the
epithelial barrier is dependent on type 1pili and binding of LPF
to glycoprotein 2 (GP2) to AIEC Disruption of Epithelial Junc-
tions microfold cells (M-cells).39,43,48 M-cells are required for
the development of host immunity,49 are involved in bacterial
sampling,50–53 and can serve as an alternative gateway for
AIEC39,54 into and through the epithelium (reviewed by
44 Shawki and McCole Cellular and Molecular Gastroenterology and Hepatology Vol. 3, No. 1Pravda55). The AIEC-containing endosome can mature into a
phagosome and exit basolaterally from the IEC,where it can be
processed by macrophages (Figure 1).42,44
After basolateral exit from epithelial cells, AIEC exposure
to lamina propria immune cells induces a proinflammatory
response and a TNF-a–dependent increase in M-cell devel-
opment,56 thereby further permitting the adherence and
invasion of AIEC and exacerbation of barrier permeability.
AIEC invasion elicits a proinflammatory response by
triggering secretion of proinflammatory cytokines from
IECs, resulting in recruitment of immune cells,13,57 and,
subsequently, NF-kB signaling,13 which allows survival of
AIEC in macrophages.58 In summary, cytokines play a key
role in the pathogenesis of AIEC and AIEC-induced epithelial
barrier dysfunction.
AIEC-Dependent Disruption of the
Apical Junctional Complex
In addition to the unknown etiology of IBD, it is uncer-
tain whether inflammation precedes epithelial barrier
dysfunction or if barrier dysfunction results in chronic
inflammation such as that observed in IBD. However, some
evidence points to an underlying barrier defect that renders
individuals susceptible to disease. First-degree relatives of
CD patients show asymptomatic barrier dysfunction asso-
ciated with subclinical immune activation, indicating that a
barrier defect may precede or is at least an early event in
the disease.59,60 In addition, altered permeability across the
intestinal epithelium is a predictor of relapse in human
CD61; whereas increased permeability precedes inflamma-
tion in rodent models,62 canine models,63 and human dis-
ease,59,64–66 and has been shown to be the underlying
mechanism of IBD in these patients. Thus, host health is
dependent on the integrity of the epithelial barrier. Patho-
logic stimuli, such as AIEC, in part influence epithelial
barrier integrity by altering the network of proteins that
regulate barrier permeability known as the intercellular
apical junctional complex (AJC).67
The AJC, comprised of several different proteins with
distinct responsibilities, directs the paracellular movement
of ions and solutes and thus is responsible to maintain
appropriate epithelial barrier permeability. The structural
units of the AJC responsible for regulating barrier integrity
and permeability are adherens junctions (AJ) and apical
TJs.17 AJs and TJs are associated with scaffolding proteins
that cooperate with the cytoskeleton of the cell providing
the AJC with a dynamic means of regulation.67 Dysregulation
of TJ proteins is observed in IBD patients (Table 1).68–71
That the AJC is required for barrier integrity has led to
the hypothesis that defects in the AJC may play a role in IBD
pathogenesis. Alteration of the AJC can occur in response to
exposure to AIEC and other enteropathogenic E coli.71–74
AIEC have been shown to decrease transepithelial elec-
trical resistance of IECs owing to disruption of the AJC.47,67
The molecular interaction of AIEC with IECs induces an
inflammatory response leading to the overproduction of
proinflammatory cytokines,75 with IFN-g and TNF-a as the
major effectors, and this is a key step in the pathogenesis ofIBD. IFN-g and TNF-a both have been shown to increase gut
permeability by acting on TJ proteins and TJ strand
complexity,76,77 which then further exacerbates barrier
dysfunction. AIEC-dependent, cytokine-induced alterations
in AJ and TJ proteins is discussed later.
CEACAM6
As previously discussed, an increase in expression of
both CEACAM6 and claudin-2 is associated with increased
barrier permeability. Interestingly, targeting of adherens
junction proteins, occludin, and claudin 3/4 and other tight
junction proteins by Helicobacter pylori, Vibrio cholera, and
enteropathogenic E coli, respectively, has been shown pre-
viously,78,79 supporting the possibility that AIEC directly
bind to TJ proteins. It has been shown that AIEC results in
increased claudin-2 expression in mice and human beings,41
and because AIEC pathogenesis is not dependent solely on
interaction of CEACAM6 with AIEC, it is possible that
claudin-2 could serve as a gateway for AIEC entry into IECs
while co-internalization of TJ proteins and AIEC may pro-
mote AIEC invasion and increased barrier permeability.
Whether AIEC are able to bind directly to TJ proteins has yet
to be shown experimentally.
Claudin-2
Distinct from the functions of adherens junctions, TJs
serve as a paracellular gateway for passive fluid movement
and solute flux and limit the passive movement of proteins
and lipids, thereby generating a concentration gradient as
well as playing a role in polarization of epithelia.71 The
conglomeration of proteins that make up the TJs include the
claudin family of transmembrane proteins, junctional
adhesion molecule-A (JAM-A), occludin, and zonula occlu-
dens members 1–3 (others not included in this article are
reviewed elsewhere67) (Figure 1).
Claudin-2 is a prominent member of the claudin family
because it forms a cation-selective pore that permits para-
cellular sodium and water flux.80,81 Overexpression of
claudin-2 results in an increase in epithelial barrier
permeability both in vitro and in vivo.82–85 IL13 and TNF-a
induce a barrier defect in UC by up-regulating claudin-2 to
facilitate the pore pathway, although IL6 also has been
shown to increase claudin-2 expression in intestinal
epithelial cells.86,87 That epithelial barrier leakiness is
related inversely to TJ strand complexity67 supports the
association of increased levels of claudin-2 with increased
barrier permeability in IBD.70,88 Conversely, a decrease in
claudin-2 expression results in a tighter epithelial barrier.89
E-cadherin
Adherens junctions are primarily responsible for cell–cell
recognition as well as initiating and maintaining cell–cell
contact and polarization.90 The major AJ protein is E-cadherin,
a transmembrane protein associatedwith the catenin family of
cytoplasmic proteins (Figure 1).90 E-cadherin plays a critical
role in adhesion of cells and is required for the formation of
TJs.91 E-cadherin single-nucleotide polymorphisms and dys-
regulation of E-cadherin are associated with IBD (reviewed by
Table 1.Major AIEC-Affected Host Junctional Proteins and Mutations Associated With IBD
Protein Gene Function Impact of AIEC Mechanisms
IBD
References
CEACAM6 CEACAM6/
CD66c/
CEAL/NCA
Bacterial pili receptor
recognizing AIEC
Increase in
expression
IFN-g and TNF-a
indirect induction
36,40
Claudin-2 CLDN2 Paracellular transport of Naþ
and H2O; regulates leak
pathway; major integral
protein of TJs
Increase in
expression
IFN-g, TNF-a, and
MLCK-dependent
internalization
92
E-cadherin CDH1 Major adherens junction
protein; cell–cell
adhesion and
communication
Displace E-cadherin
in vitro
Presumed TNF-a, IFN-g,
and MLCK-induced
internalization; cleavage?
47,91,93
JAM-A F11R Regulator of TJ assembly;
leukocyte transmigration
Decrease in
expression
Presumably macrophage
release of
proinflammatory cytokines
69,94
MLCK MYLK Phosphorylates myosin
regulatory light chains
to facilitate myosin
interaction with actin
filaments to produce
contractile activity;
membrane distribution
(and redistribution) of
TJ proteins
Down-regulation
of ZO-1,
redistribution
of TJ proteins
TNF-a–dependent activation
of NF-kB and activation
of MLCK
67,95
NOD2 CARD15 Recognition of pathogen-
associated molecular
patterns; bacterial
sensing; drive
autophagolysis of bacteria
containing phagosomes
Decrease in expression;
indirect: LPS binding
with NOD2 results
in autophagolysis
of AIEC
Endocytosis
activation of NF-kB leading
to dysregulated
proinflammatory response
and promotes invasion
of AIEC
20,21,35
Occludin OCLN Integral TJ protein involved
in stability and cytokine-
induced regulation of TJs
Redistribution/down-
regulation of
occludin
Induction of TNF-a,
activation of MLCK
69,96
Partitioning
defective
protein-3
(PAR-3)
PARD3 Asymmetric cell growth;
cell polarization;
targeting of TJ proteins
to membrane
Unknown Presumably disruption of
adherens junctions resulting
in increased Cldn-2 and
decreased membrane
localization of ZO-1
91,97
Zonula
occludens-1
TJP1 Plaque protein; scaffolding
of TJ proteins to the
cytoskeleton
Disruption of
ZO-1 resulting
in increased
appearance of gaps
between cells
Presumably TNF-a, IFN-g,
and MLCK- induced
internalization
47,92,93
January 2017 AIEC Disruption of Epithelial Junctions 45McCole91), supporting a role for AJ defects in IBD-associated
barrier dysfunction.67 Furthermore, AIEC, in addition to
other intestinal pathogens,91 are able to displace E-cadherin
in vitro,47,93 potentially providing another mechanism of
invasion and barrier disruption.
Junctional Adhesion Molecule
JAM-A is another PSD95-DlgA-zonula occludens-1 ho-
mology domain (PDZ)-domain–containing integral protein
localized to TJs.98 JAM-A shows PDZ-domain–dependent
interactions with the scaffolding protein zonula occludens 1
(ZO-1) and cell polarity partitioning defective protein-3.99
Expression of JAM-A was shown to be decreased69
together with ZO-1100 in IBD, and loss of JAM-A results inincreased epithelial barrier permeability.101,102 It is un-
known whether AIEC directly results in the down-regulation
of JAM-A or if it is a consequence of down-regulation of
ZO-1; however, AIEC may regulate JAM-A indirectly via the
release of inflammatory cytokines from infected macro-
phages.94 Nevertheless, it is possible that AIEC, in addition
to altering ZO-1, may alter JAM-A and partitioning defective
protein-3–dependent targeting of TJ proteins to the mem-
brane,97 resulting in disrupted TJ complex integrity and
altered cell polarity, further promoting IBD pathogenesis.
Occludin
Occludin, a 65-kilodalton integral transmembrane pro-
tein, is involved in the stability and regulation of TJs.103
46 Shawki and McCole Cellular and Molecular Gastroenterology and Hepatology Vol. 3, No. 1Although down-regulation of occludin is observed in CD and
UC patients,69 the UC-associated proinflammatory cytokine
IL13 alone was not able to abolish occludin protein levels in
a colorectal cancer cell line (HT-29).86 This discrepancy was
attributed to a dilution of the number of cells isolated from
the inflamed tissue of UC patients. Nevertheless, it has been
shown from in vitro work that occludin plays a key role in
promoting barrier function and is redistributed away from
tight junctions after enterohemorrhagic E coli infection of
human colonoid monolayers.17,74 Further work to elucidate
the in vivo role of occludin is needed because mice lacking
occludin do not show defects in TJ morphology despite
histologic abnormalities in some tissues.104 Proin-
flammatory cytokine-dependent phosphorylation of myosin
light chain (MLC) by myosin light chain kinase (MLCK) or
Rho-associated kinase results in rapid reorganization of the
AJC.67,96,105 Although it remains to be confirmed, AIEC could
affect occludin distribution indirectly through bacteria-
dependent induction of proinflammatory cytokines from
immune cells, activation of MLCK or Rho-associated kinase,
and subsequent redistribution of occludin.
Zonula Occludens
ZO is a PDZ homology domain containing plaque protein
involved in scaffolding of TJ proteins to the cytoskeleton.106
ZO-1, -2, and -3 contain PDZ domains that facilitate
anchorage of TJ proteins such as claudins,107 occludin,108 and
JAM-A100 to the cytoplasm and thereby play a key role in TJ
formation and regulation. TNF-a induces an increase in TJ
permeability via NF-kB–dependent down-regulation of ZO-1
protein and MLCK-dependent95,96,109–111 redistribution of
TJ proteins76 in an apoptosis-independentmanner (reviewed
by Bruewer et al67). Similarly, AIEC disrupt TJ composition by
altering ZO-1, resulting in increased appearance of gaps be-
tween cells.47,93 Conversely, probiotic and commensal bac-
teria promote up-regulation of ZO proteins and strengthening
of the epithelial barrier (reviewed by Ulluwishewa et al112),
potentially supporting the notion that when probiotic bacte-
ria outcompete pathogens, this not only will return the bal-
ance of the microbiota, but also enable restitution of the TJ
complex.
In the absence of bacteria, regulation of the AJC is
mediated by the interaction of the cytoskeleton with the
proteins of the AJC or by cytokines. IFN-g induces macro-
pinocytosis92 of occludin, JAM-A, and claudin-1 via myosin
2–dependent vacuolarization of the apical membrane105
into early endosomes, resulting in an increase in barrier
permeability.113 That AIEC also are internalized by macro-
pinocytosis illustrates a direct disruption of the AJC by the
bacteria and establishes an additional virulence factor for
the invasion of AIEC.
Conclusions
Data to date clearly support the notion that IBD patho-
genesis is dependent on dysregulation of multiple factors
including disruption of the intestinal barrier and immune
dysregulation, and is associated with profound alterations in
gut microbial communities. Altered intestinal homeostasisdrives expansion of AIEC and results in compromised bar-
rier function. AIEC are able to invade, survive, and replicate
within host cells, leading to exacerbation of barrier
dysfunction by disruption of TJ proteins, and ultimately
contributing to IBD pathogenesis. Recent clinical findings
have indicated that AIEC is not associated exclusively with
ileal CD. If AIEC does indeed play an important role in IBD
pathogenesis it will be vital to better understand unresolved
questions regarding its appearance in disease. Specifically:
(1) what are the host genetic and environmental factors that
promote AIEC expansion in some patients but not all; (2)
how is regional variation in AIEC expansion determined;
and (3) can therapeutic interventions (probiotics, prebiotics,
small molecules) specifically neutralize or modify AIEC
pathogenic behavior? AIEC are capable of compromising
intestinal epithelial barrier properties both directly and
indirectly to enhance their pathogenic impact. Therefore, in
addition to the earlier-described approaches, it will be of
key interest to determine if strategies designed to enhance
the epithelial barrier can minimize the pathogenic impact of
AIEC and its putative contribution to IBD.References
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